 | |
| Clinical data | |
|---|---|
| Other names | BTRX-140; CYM-53093; NMRA-140; NMRA-335140 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C25H32FN5O2 |
| Molar mass | 453.562 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is an opioid antagonist medication which is under development for the treatment of depression.[1][2][3] It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder.[1][2][3] As of December 2023, navacaprant is in phase 3 clinical trials for this indication.[4]
See also[edit]
References[edit]
- ^ a b "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.
- ^ a b "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
- ^ a b Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.
- ^ Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.
External links[edit]